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Abstract
A key challenge in genomics is to identify genetic variants that distinguish patients with different
survival time following diagnosis or treatment. While the log-rank test is widely used for this purpose,
nearly all implementations of the log-rank test rely on an asymptotic approximation that is not appropri-
ate in many genomics applications. This is because: the two populations determined by a genetic variant
may have very different sizes; and the evaluation of many possible variants demands highly accurate
computation of very small p-values. We demonstrate this problem for cancer genomics data where the
standard log-rank test leads to many false positive associations between somatic mutations and survival
time. We develop and analyze a novel algorithm, Exact Log-rank Test (ExaLT), that accurately com-
putes the p-value of the log-rank statistic under an exact distribution that is appropriate for any size
populations. We demonstrate the advantages of ExaLT on data from published cancer genomics studies,
finding significant differences from the reported p-values. We analyze somatic mutations in six cancer
types from The Cancer Genome Atlas (TCGA), finding mutations with known association to survival
as well as several novel associations. In contrast, standard implementations of the log-rank test report
dozens-hundreds of likely false positive associations as more significant than these known associations.
Introduction
Next-generation DNA sequencing technologies are now enabling the measurement of exomes, genomes,
and mRNA expression in many samples. The next challenge is to interpret these large quantities of DNA
and RNA sequence data. In many human and cancer genomics studies, a major goal is to find associations
between an observed phenotype and a particular variable (e.g., a single nucleotide polymorphism (SNP), so-
matic mutation, or gene expression) from genome-wide measurements of many such variables. For example,
many cancer sequencing studies aim to find somatic mutations that distinguish patients with fast-growing
tumors that require aggressive treatment from patients with better prognosis. Similarly, many human dis-
ease studies aim to find genetic alleles that distinguish patients who respond to particular treatments, i.e.
live longer. In both of these examples one tests the association between a DNA sequence variant and the
survival time, or length of time that patients live following diagnosis or treatment.
The most widely approach to determine the statistical significance of an observed difference in survival
time between two groups is the log-rank test [29, 41]. An important feature of this test, and related tests in
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survival analysis [25], is their handling of censored data: in clinical studies, patients may leave the study
prematurely or the study may end before the deaths of all patients. Thus, a lower bound on the survival
time of these patients is known. Importantly, many studies are designed to test survival differences between
two pre-selected populations that differ by one characteristic; e.g. a clinical trial of the effectiveness of a
drug. These populations are selected to be approximately equal in size with a suitable number of patients
to achieve appropriate statistical power (Fig. 1A). In this setting, the null distribution of the (normalized)
log-rank statistic is asymptotically (standard) normal; i.e. follows the (standard) normal distribution in the
limit of infinite sample size. Thus, nearly every available implementation (e.g., the LIFETEST procedure in
SAS, and the survdiff package in R and SPlus) of the log-rank test computes p-values from the normal
distribution, an approximation that is accurate asymptotically (see Supporting Information).
The design of a genomics study is typically very different from the traditional clinical trials setting. In
a genomics study, high-throughput measurement of many genomics features (e.g. whole-genome sequence
or gene expression) in a cohort of patients is performed, and the goal is to discover those features that
distinguish survival time. Thus, the measured individuals are repeatedly partitioned into two populations
determined by a genomic variable (e.g. a SNP) and the log-rank test, or related survival test, is performed
(Fig. 1B). Depending on the variable the sizes of the two populations may be very different: e.g. most
somatic mutations identified in cancer sequencing studies, including those in driver genes, are present in
< 20% of patients [9, 8, 7, 10, 16, 44]. Unfortunately, in the setting of unbalanced populations, the normal
approximation of the log-rank statistic gives poor results.
While this fact has been noted in the statistics literature [28, 27], it is not widely known, and indeed
the normal approximation to the log-rank test is routinely used to test the association of somatic mutations
and survival time (e.g. [24, 15] and numerous other publications). A second issue in genomics setting is
that the repeated application of the log-rank test demands the accurate calculation of very small p-values,
as the computed p-value for a single test must be corrected for the large number of tests; e.g. through a
Bonferroni or other multiple-hypothesis correction. An inaccurate approximation of p-values will result in
an unacceptable number of false positives/negative associations of genomic features with survival. These
defining characteristics of genomics applications, unbalanced populations and necessity of highly-accurate
p-values for multiple-hypothesis correction, indicate that standard implementations of the log-rank test are
inadequate.
We propose to compute the p-value for the log-rank test using an exact distribution determined by the
observed number of individuals in each population. Perhaps the most famous use of an exact distribution is
Fisher’s exact test for testing the independence of two categorical variables arranged in a 2× 2 contingency
table. When the counts in the cells of the table are small, the exact test is preferred to the asymptotic
approximation given by the χ2 test [14]. Exact tests for comparing two survival distributions have received
scant attention in the literature. There are three major difficulties in developing such a test. First, there are
multiple observed features that determine the exact distribution including the number of patients in each
population and the observed censoring times. With so many combinations of parameters it is infeasible
to pre-compute distribution tables for the test. Thus, we need an efficient algorithm that computes the
p-value for any given combination of observed parameters. Second, we cannot apply a standard Monte-
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Carlo permutation test to this problem since we are interested in very small p-values that are expensive to
accurately estimate with such an approach1. Third, there are two possible null distributions for the log-
rank test, the conditional and the permutational [41, 31, 30, 18]. While both of these distributions are
asymptotically normal, the permutational distribution is more appropriate for genomics settings [41, 4], as
we detail below. Yet no efficient algorithm is known to compute the p-value of the log-rank test under the
exact permutational distribution.
We introduce an efficient and mathematically sound algorithm, called ExaLT (for Exact Log-rank Test),
for computing the p-value under the exact permutational distribution. The run-time of ExaLT is not function
of the p-value, enabling the accurate calculation of small p-values. In contrast to other heuristic approaches,
ExaLT returns a conservative estimate of the p-value, thus guaranteeing rigorous control on the number of
false discoveries. We test ExaLT on data from two published cancer studies [22, 47], finding substantial
differences between the p-values obtained by our exact test and the approximate p-values obtained by stan-
dard tools in survival analysis. In addition, we run ExaLT on somatic mutation and survival data from The
Cancer Genome Atlas (TCGA) and find a number of mutations with significant association with survival
time. Some of these such as IDH1 mutations in glioblastoma are widely known; for others such as BRCA2
and NCOA3 mutations in ovarian cancer there is some evidence in the literature; while the remaining are
genuinely novel. Most of these are identified only using the exact permutational test of ExaLT. In contrast,
the genes reported as highly significant using standard implementations of the log-rank test are not sup-
ported by biological evidence; moreover, these methods report dozens-hundreds of such likely false positive
associations as more significant than known genes associated with survival. These results show that our
algorithm is practical, efficient, and avoids a number of false positives, while allowing the identification of
genes known to be associated with survival and the discovery of novel, potentially prognostic biomarkers.
Materials and Methods
Background: The Log-Rank Test
We focus here on the two-sample log-rank test of comparing the survival distribution of two groups, P0 and
P1. Let t1 < t2 < · · · < tk be the times of observed, uncensored events. LetRj be the number of patients at
risk at time tj , i.e. the number of patients that survived (and were not censored) up to this time, and let Rj,1
be the number of P1 patients at risk at that time. Let Oj be the number of observed uncensored events in the
interval [tj−1, tj ], and let Oj,1 be the number of these events in group P1. If the survival distributions of P0
and P1 are the same, then the expected value E[Oj,1] = Oj
Rj,1
Rj
. The log-rank statistic [29, 41] measures
the sum of the deviations of Oj,1 from the expectation,2 V =
∑k
j=1
(
Oj,1 −Oj Rj,1Rj
)
.
Under the null hypothesis of no difference in the survival distributions of the two groups, E[V ] = 0,
and Pr(|V | ≥ |v|) is the p-value of an observed value v. Two possible null distributions are considered in
the literature, the permutational distribution and the conditional distribution (see Figure S1).
1The user manual of StatXact [15], a popular software package for exact inference, reports that, in general, a few hours
might be necessary to obtain p-values accurate to 10−3 using Monte-Carlo permutation tests.
2In some clinical applications one is more interested in either earlier or later events. In that case the statistic is a weighted sum
of the deviations. Our results easily translate to the weighted version of the test.
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Permutational Log-Rank Test
In the permutational log-rank test [41], the null distribution is obtained by assigning each patient to popula-
tion P0 or P1 independently of the survival time. Let n be the total number of patients, and n1 the number of
patients in group P1. We consider the sample space of all
(
n
n1
)
possible selections of survival times and cen-
soring information from the observed data for the n1 patients of group P1. Each such selection is assigned
equal probability
(
n
n1
)−1.
Conditional Log-Rank Test
In the conditional log-rank test [31], the null distribution is defined by conditioning on Oj and Rj,1 for
j = 1, . . . , k. If at time tj there are a total of Rj patients at risk, including Rj,1 patients in P1, then under
the assumption of no difference in the survival of P0 and P1 the Oj events at time tj are split between P0
and P1 according to a hypergeometric distribution with parameters Rj , Rj,1, and Oj .
Choice of Null Distribution and Estimation of p-values
We considered the two versions of the log-rank test, the conditional [31] and the permutational [41]. The
conditional null distribution for the log-rank test is preferred in clinical trials because it does not assume
equal distribution of censoring in the two populations. This is important in clinical trials when patients
in the two groups are subject to different treatments that may affect their probability of leaving the trial.
However, unequal censoring is not a concern in genome studies, since we do not expect a DNA sequence
variant to influence a patient’s decision to leave the trial. In both null distributions the prefix sums of the
log-rank statistic define a martingale, and by the martingale central limit theorem [25], the normalized log-
rank statistic has an asymptotic N (0, 1) distribution. The normalizing variance is different in the two null
distributions, but asymptotically the two variances are the same [30], leading to the same p-values in the
two versions of the test for large balanced populations. Therefore, the distinction between the two versions
of the test is largely ignored in practice, where most papers that use the log-rank test or software packages
that implement the test do not document the specific test. This can be explained, in part, by the widespread
use of the log-rank in other scenarios, like clinical trials, where the issues specific to genomic settings do
not arise. The differences between the tests are also rarely discussed in the literature, although there is some
discussion [4, 30] on which variance is the appropriate one to use to compute p-values from the asymptotic
approximation.
In the case of small and unbalanced populations, the two null distributions yield different p-values, and
the normal approximation gives poor estimates of both (Fig. S2). On simulations of cancer data, we found
that the p-values from the permutational exact test are significantly closer to the empirical p-values than the
p-values obtained from the conditional exact test (Fig. S3 and Supplemental Text). Moreover, we prefer the
permutational null distribution because it better models the null hypothesis for mutation data and has greater
power.
While the exact computation of p-values in the conditional null distribution can be computed in poly-
nomial time using a dynamic programming algorithm [20], no polynomial time algorithm is known for the
exact computation of the p-value in the permutational null distribution: current implementations are based
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on a complete enumeration algorithm, making its use impractical for large number of patients3. Several
heuristics have been developed for related computations including: saddlepoint methods to approximate the
mid-p-values [1], methods based on the Fast Fourier Transform (FFT) [26, 36, 38], and branch and bound
methods [2]. Such heuristics are shown to be asymptotically correct, converging to the correct p-value as
the number of samples and computation time grows to infinity. However, no explicit bounds are known for
the accuracy of the computed p-value when these heuristics are applied to a fixed sample size and under a
bounded computation time. Given the systematic error we report below for the standard implementation of
the log-rank test, we argue that such guarantees are essential in this and many similar settings.
ExaLT
We developed an algorithm, Exact Log-rank Test (ExaLT), to compute the p-value of the log-rank statistic
under the exact permutational distribution. In particular, we designed a fully polynomial time approximation
scheme (FPTAS) for computing the p-value under the permutational distribution. Our algorithm gives an
explicit bound on the error in approximating the true p-value, for any given sample size, in polynomial time.
Furthermore, the output of our scheme is always a conservative or valid p-value estimate.
Since the log-rank statistic depends only on the order of the events and not on their actual times, we
can w.l.o.g. treat the survival data (including the censored times) as an ordered sequence of events, with no
two patients having identical survival times. Let nj = |Pj |, for j = 0, 1, be the number of patients in each
population and let n = n0 +n1 be the total number of patients. We represent the data by two binary vectors
x ∈ {0, 1}n and c ∈ {0, 1}n, where xi = 1 if the ith event was in P1 and xi = 0 otherwise; ci = 0 if the ith
event was censored and ci = 1 otherwise. Note that n1 =
∑n
i=1 xi. In this notation the log-rank statistic is
V = V (x, c) =
n∑
j=1
cj
(
xj − n1 −
∑j−1
i=0 xi
n− j + 1
)
. (1)
Let Vt(x) =
∑t
j=1 cj(xj − n1−
∑j−1
i=0 xi
n−j+1 ) be the test statistic V (x) at time t. Note that since n, n1, and
c are fixed, the statistic depends only on the value of x. Assume the observed log-rank statistic has value v.
The p-value of the observation v is the probability Pr(|V (x)| ≥ |v|) computed in the probability space in
which the n1 events of P1 are uniformly distributed among the n events.
For any 0 ≤ t ≤ n and 0 ≤ r ≤ n1, let P (t, r, v) = Pr(Vt(x) ≤ v and
∑t
i=1 xi = r) denote the
joint probability of Vt(x) ≤ v and exactly r events from P1 occur in the first t events. Let Q(t, r, v) =
Pr(Vt(x) ≥ v and
∑t
i=1 xi = r). denote the joint probability of Vt(x) ≥ v and exactly r events from P1
occur in the first t events.
At time 0: P (0, r, v) = 1 if r = 0 and v ≥ 0, otherwise P (0, r, v) = 0. Similarly Q(0, r, v) = 1 if
r = 0 and v ≤ 0, otherwise Q(0, r, v) = 0.
Given the values of P (t, r, v) for all v and r, we can compute the values of P (t + 1, r, v) using the
3The StatXact manual recommends using the enumeration algorithm only when the number of samples is at most 20.
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following relations: If ct+1 = 1 then
P (t+ 1, r, v) = (1− n1−rn−t )P (t, r, v + n1−rn−t )
+ n1−(r−1)n−t P (t, r − 1, v − (1− n1−(r−1)n−t )).
If ct+1 = 0 then
P (t+ 1, r, v) = (1− n1 − r
n− t )P (t, r, v) +
n1 − (r − 1)
n− t P (t, r − 1, v).
Analogous equations hold for Q(t, r, v).
The process defined by these equations guarantees that the n events always include n1 events of P1.
Thus, the p-value of the observation v is given by Pr(|V (x)| ≥ |v|) = P (n, n1,−|v|) +Q(n, n1, |v|).
For fixed t and r, P (t+1, r, v) andQ(t+1, r, v) are step functions. For example, if ct+1 = 1, then as we
vary v, P (t+1, r, v) changes only at the points in whichP
(
t, r, v + n1−rn−t
)
orP
(
t, r − 1, v −
(
1− n1−(r−1)n−t
))
change values. Thus, we only need to compute the function P (t+ 1, r, v) at these points. At t = 0 the func-
tion P (0, r, v) assumes up to 2 values. If P (t, r, v) assumes m(t, r) values and P (t, r − 1, v) assumes
m(t, r − 1) values, then P (t+ 1, r, v) assumes up to m(t, r) +m(t, r − 1) values.
Similar relations hold for P (t + 1, r, v) when ct+1 = 0, and for computing Q(t, r, v) in the two cases.
Thus, in n iterations the process computes the exact probabilities P (n, r, v) and Q(n, r, v), but it may have
to compute probabilities for an exponential number of different values of v in some iterations.
We construct a polynomial time algorithm by modifying the above procedure to compute the probabili-
ties of only a polynomial number of values in each iteration. We first observe that since the probability space
consists of
(
n
n1
)
equal probability events, all non-zero probabilities in our analysis are ≥ n−n1 . For ε > 0,
fix ε1 such that (1 − ε1)−n = 1 + ε. Note that 1 = O(/n). We discretize the interval of possible non-
zero probabilities [n−n1 , 1], using the values (1 − ε1)k, for k = 0, . . . , ` = −n1 lognlog(1−ε1) = O(ε−1nn1 log n).
The approximation algorithm estimates P (t, r, v) with a step function P˜ (t, r, v) defined by a sequence of `
points vtk,r, k = 0, . . . , `, such that v
t
k,r is an estimate for the largest v such that P (t, r, v) ≤ (1− ε1)k. We
prove that if iteration t computes a function P˜ (t, r, v)(1− 1)t ≤ P (t, r, v) ≤ P˜ (t, r, v), then starting from
P˜ (t, r, v) the t+1 iteration computes an estimate P˜ (t+1, r, v)(1−1)t+1 ≤ P (t+1, r, v) ≤ P˜ (t+1, r, v).
(Fig. S4 provides the intuition for how the approximation at time t+ 1 is computed from the approximation
at time t.) Thus, after n iterations we have an -approximations for P (n, n1, v). Similar computations obtain
an -approximation for Q(n, n1, v). The details of the algorithm and analysis are given in the Supporting
Information.
We implemented the FPTAS in our software ExaLT and evaluated its performance as n and ε varies,
and by comparing its running time with the running time of the exhaustive enumeration algorithm for the
permutational test (Fig. S5). Our implementation of the FPTAS is very efficient, with significant speed-up
compared to the exhaustive algorithm. The C++ implementation of ExaLT and a R package to run ExaLT are
available at http://compbio.cs.brown.edu/projects/exactlogrank/.
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Synthetic Data
We used synthetic data to assess the accuracy of the asymptotic approximations. We generated data as fol-
low: when no censoring was included, we generated the survival times for the patients from an exponential
distribution, and the group labeling (mutated or not) were assigned to patients independently of their survival
time; when censoring in f% of the patients was included, we selected f% of the patients to have censored
survival time independently of their survival time and group. The censoring time was assumed to happen
just before the observed survival time.
We used synthetic data to compare the empirical p-value and the p-values from the exact tests as well.
In this case we generated synthetic data using two related but different procedures. In the first procedure, we
mutate a gene g in exactly a fraction f of all patients. In the second procedure, we mutated a gene g in each
patient independently with probability f . The second procedure models the fact that mutations in a gene g
are found in each patient independently with a certain probability. In both cases the survival information
is generated from the same distribution for all patients. The survival time comes from the exponential
distribution with expectation equal to 30, and censoring variable from an exponential distribution resulting
in 30% of censoring.
Mutation and Clinical TCGA Data
We analyzed somatic mutation and clinical data, including survival information, from the public TCGA data
portal (https://tcga-data.nci.nih.gov/tcga/). In particular we considered single nucleotide
variants and small indels for colorectal carcinoma (COADREAD), glioblastoma multiforme (GBM), kidney
renal clear cell carcinoma (KIRC), lung squamous cell carcinoma (LUSC), ovarian serous adenocarcinoma
(OV), and uterine corpus endometrial carcinoma (UCEC). We restricted our analysis to patients for which
somatic mutation and survival data were both available. We only considered genes mutated in > 1% of
patients. Since genes mutated in the same set of patients would have the same association to survival,
they are all equivalent for an automated analysis of association between mutations and survival; we then
collapsed them into metagenes, recording the genes that appear in a metagene. In our experiments we used
ExaLT to compute the exact permutational p-value whenever the mutation frequency of a gene was ≤ 10%,
and we used the asymptotic approximation for genes with mutations frequency higher than 10%, since our
simulations shows that the approximation is accurate for the range of parameters considered (see Supporting
Information).
Results
Accuracy of Asymptotic Approximations
We first assessed the accuracy of the asymptotic approximation for the log-rank test on simulated data from
a cohort of 500 patients with a gene g mutated in 5% of these patients, a frequency that is not unusual
for cancer genes in large-scale sequencing studies [9, 8, 7, 10]. We compared the survival times of the
population P(g) of patients with a mutation in g to the survival of the population P¯(g) of patients with
no mutation in g. We computed p-values using R survdiff on multiple random instances (in order to
obtain a distribution for the p-value of g) in which P(g) and P¯(g) have the same survival distribution.
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Fig. S2 in Supporting Information shows the difference between the p-values computed by the asymptotic
approximation are much smaller than expected under the null hypothesis, with the smallest p-values showing
the largest deviation from the expected uniform distribution.
The inaccuracy of the asymptotic log-rank test results in a large number of false discoveries: for example,
considering a randomized version of a cancer mutation dataset (Table S1) in which no mutation is associated
with survival (i.e. no true positives), the asymptotic log-rank test reports 110 false discoveries (Bonferroni
correction) or 291 false discoveries (False Discovery Rate (FDR) correction), with significance level α =
0.05 (Fig. 1). We found that the inaccuracy of the asymptotic log-rank test results mostly from the imbalance
in the sizes of the two populations, rather than the total number of patients or the number of patients in the
smaller population (see Fig.S2a-d and Supporting Text).
Published Cancer Studies
To demonstrate the applicability of ExaLT we compared the p-values from the exact distribution to p-
values from the asymptotic approximation reported in two recently published cancer genomics studies [22,
47]. Huang et al. [22] divides patients into groups defined by the number of risk alleles of five single
nucleotide polymorphisms (SNPs), and compares the survival distribution of the resulting populations. In
one comparison, the survival distribution of 2 patients (13% of total) with at most 2 risk alleles was compared
with the survival distribution of 14 patients with more than 2 risk alleles, and a p-value of 0.012 is reported.
Thus, this association is significant at the traditional significance level of α = 0.05. However, ExaLT
computes an exact p-value of 0.17, raising doubts about this association. In another comparison patients at
a different disease stage were considered, and the division of the patients into groups as above resulted in
comparing the survival distribution of 8 patients (17% of total) with the survival distribution of 40 patients,
and a p-value of 6×10−6 is reported. In contrast, ExaLT computes an exact p-value of 2×10−3, a reduction
of three orders of magnitude in the significance level. Additional comparisons are shown in the Supporting
Information.
In [47], the survival distribution of 14 glioblastoma patients (11% of total) with somatic IDH1 or IDH2
mutations was compared to the survival distribution of 115 patients with wild-type IDH1 and IDH2. The
reported p-value from the asymptotic approximation is 2 × 10−3, while the exact permutational p-value is
5×10−4, indicating a stronger association between somatic mutations in IDH1 or IDH2 and (longer) survival
than reported. Notably, this same association has been reported in three other glioblastoma studies [37, 35,
21].
TCGA Cancer data
We analyzed somatic mutation and survival data from studies of six different cancer types (Table S1) from
The Cancer Genome Atlas (TCGA). For each mutated gene, we compared the p-value obtained using the
asymptotic approximation as computed by the R package survdiff to the exact p-value as computed by
ExaLT(Tables S2-S4). Fig. 2 shows the exact p-values and the R survdiff p-values for the glioblastoma
multiforme (GBM) dataset and ovarian serous adenocarcinoma (OV) dataset. The p-values for the other
datasets are shown in Fig. S6.
For most datasets the asymptotic p-values obtained from R survdiff are very different from the ones
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obtained with the exact p-values obtained by ExaLT, and the ranking of the genes by p-value is very different
as well (see Supporting Information). For example, in GBM none of the top 25 genes reported by R are in
the list of the top 25 genes reported by the exact permutational test. Since genomics studies are typically
focused on the discovery of novel hypotheses that will be further validated, this striking difference in the
ranking of genes by the two algorithms is important: a poor ranking of genes by their association with
survival will lead to many false discoveries undergoing additional experimental validation. While several of
genes ranked in the top 10 by ExaLT are known to have mutations associated with survival (Table 1), none of
the top 10 genes reported by R survdiff (Table S4) have mutations known to be associated with survival.
R survdiff ranks dozens-hundreds of presumably false positives associations as more significant than
these known genes. Moreover, R survdiff reports extremely strong association with survival for many of
these higher ranked, but likely false positive, genes; e.g., in uterine corpus endometrial carcinoma (UCEC),
13 genes have p < 10−8 and an additional 19 genes have p < 10−5, but none of these have a known
association with survival.
The top 10 genes reported by ExaLT contain several novel associations that are supported by the liter-
ature and are not reported using R survdiff. In GBM, ExaLT identifies IDH1 (p ≤ 7 × 10−5), VARS2
(p ≤ 8 × 10−3) and GALR1 (p ≤ 9 × 10−3), among others. As noted above, the association between
mutations in IDH1 and survival has been previously reported in GBM [47, 37, 35, 21]. A germline vari-
ant in VARS2 has been reported to be a prognostic marker, associated with survival, in early breast cancer
patients [11]. The expression of GALR1 has been reported to be associated with survival in colorectal
cancer [43], and its inactivation by methylation has been associated with survival in head and neck can-
cer [34, 33]. In OV, ExaLT identifies BRCA2 (p ≤ 7 × 10−3) and NCOA3 (p ≤ 3 × 10−3), and others.
Germline and somatic mutations in BRCA2 (and BRCA1) have been associated with survival in two ovar-
ian cancer studies [3, 9]. A polymorphism in NCOA3 has been associated with breast cancer [6], and its
amplification has been associated with survival in ER-positive tumors [5].
Thus, the exact test implemented by ExaLT appears to have higher sensitivity and specificity in detecting
mutations associated with survival on the sizes of cohorts analyzed in TCGA. Finally, we note that the exact
conditional test obtains results similar to R survdiff, confirming that the the exact permutational test
implemented by ExaLT is a more appropriate exact test for genomics studies. (See Supporting Information.)
Discussion
In this work we focus on the problem of performing survival analysis in a genomics setting, where the
populations being compared are not defined in advance, but rather are determined by a genomic measure-
ment. The two distinguishing features of such studies are that the populations are typically unbalanced and
that many survival tests are performed for different measurements, requiring highly accurate p-values for
multiple hypothesis testing corrections. We show empirically that the asymptotic approximations used in
available implementations of the log-rank test produce anti-conservative estimates of the true p-values when
applied to unbalanced populations, resulting in a large number of false discoveries. This is not purely a phe-
nomenon of small population size: the approximation remains inaccurate even for a large number of samples
(e.g., 100) in the small population. This inaccuracy makes asymptotic approximations unsuitable for can-
cer genomic studies, where the vast majority of the genes are mutated in a small proportion of all samples
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[7, 9, 8] and also for genome-wide association studies (GWAS) where rare variants may be responsible for
a difference in drug response or other phenotype.
The problem with the log-rank test for unbalanced populations has previously been reported [28, 27],
but the implications for genomics studies have not received attention. Note that the issue of unbalanced
populations is further exacerbated by any further subdivision of the data: e.g. by considering mutations
in specific locations or protein domains; by considering the impact of mutations on a specific therapeutic
regimen; by testing the association of mutations with survival in a particular subtype of cancer; by grouping
into more than two populations; or by correcting for additional covariates such as age, stage, grade, etc. All
of these situations occur in genomics studies.
We considered the two versions of the log-rank test, the conditional [31] and the permutational [41], and
we found that the exact permutational distribution is more accurate in genomics settings. We introduce Ex-
aLT, the first efficient algorithm to compute highly accurate p-values for the exact permutational distribution.
We implemented and tested our algorithm on data from two published cancer studies, showing that the exact
permutational p-values are significantly different from the p-values obtained using the asymptotic approxi-
mations. We also ran ExaLT on somatic mutation and survival data from six cancer types from The Cancer
Genome Atlas (TCGA), showing that our algorithm is practical, efficient, and allows the identification of
genes known to be associated with survival in these cancer types as well as novel associations.
While our focus here was the log-rank test, our results are relevant to more general survival statistics.
First, in some survival analysis applications, samples are given different weights; our algorithm can be easily
adapted to a number of these different weighting schemes. Second, an alternative approach in survival anal-
ysis is to perform linear regression using the Cox Proportional-Hazards model [25]. Testing the significance
of the resulting coefficients in the regression is typically done using a test that is equivalent to the log-rank
test, and thus our results are relevant for this approach as well. See Supporting Information.
The challenges of extending multivariate regression models to the multiple-hypothesis setting of genome-
wide measurements is not straightforward. Direct application of such a multivariate Cox regression will
often not give reasonable results as: there are a limited number of samples and a large number of genomic
variants; and many variants are rare and not associated with survival. Witten and Tibshirani (2010) [46]
recently noted these difficulties for gene expression data stating that: “While there are a great number of
methods in the literature for identification of significant genes in a microarray experiment with a two-class
outcome . . . the topic of identification of significant genes with a survival outcome is still relatively unex-
plored.” We propose that exact tests such as the one provided here will be useful building blocks for more
advanced models of survival analysis in the genomics setting.
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Figure 1: Difference between survival analysis in a clinical setting with balanced populations and genomics setting,
with unbalanced populations. (A) In a typical clinical study, two pre-selected groups of similar size are compared.
Because the groups are balanced and each has a suitable number of patients, the asymptotic approximation (normal
distribution) used in common implementations of the log-rank test gives an accurate approximation of the exact dis-
tribution, resulting in accurate p-values. (B) In a genomics study, the two groups are defined by a genetic variant. In
many cases, the sizes of the groups are unbalanced, with one group being much larger than the other. In this situation,
the asymptotic distribution does not accurately approximate the exact distribution of the log-rank statistic, and the
resulting p-values computed from the tail of the distribution (see inset) are inaccurate.
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Figure 2: Differences between observed and expected p-values from different forms of the log-rank test on a random-
ized cancer dataset consisting of somatic mutations in 6184 genes. The p-values for the genes should be distributed
uniformly (green line), since there is no association between mutations and survival in this random data. Asymptotic
approximations of the log-rank statistic (purple and blue) yield p-values that deviate significantly from the uniform
distribution, incorrectly reporting many genes whose mutations are significantly associated with survival. In particular,
the asymptotic log-rank test in R reports 110 genes with significant association, using a Bonferroni corrected p-value
< 0.05 (black line), or 291 genes with significant association using a less conservative FDR = 0.05. In contrast, the
exact test makes no false discoveries.
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Table 1: Genes with mutations previously reported to associated with survival that were identified by ExaLT. For each
gene we show: the cancer type in which the gene is identified; the rank and p-value using the exact permutational test
computed by ExaLT and the approximate test computed by thesurvdiff package in R ; the number of samples with
a mutation in the gene; and references supporting the association of mutations with survival.
ExaLT (exact permutational) R survdiff (asymptotic)
gene cancer type rank p rank p num. mut. refs
KRAS COADREAD 4 1.3e-02 82 1.4e-02 85 [19]
FBXW7 COADREAD 10 5.6e-02 142 5.8e-02 21 [7]
IDH1 GBM 1 6.7e-05 27 3.8e-03 15 [37, 35]
BAP1 KIRC 9 9.7e-03 98 1.2e-02 27 [17]
BRCA2 OV 6 6.2e-03 32 3.5e-02 9 [9, 3]
ARID1A UCEC 5 9.7e-03 219 1.2e-02 73 [45]
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Supplementary Information: Accurate Computation of Survival Statistics in
Genome-wide Studies
Implementations of the log-rank test
Common statistical packages provide implementations4 of the log-rank test for the following distributions:
• asymptotic conditional: SAS (LIFETEST), R and S-Plus (survdiff), SPSS, GraphPad Prism.
• asymptotic permutational and exact permutational: StatXact.
Background
Model
Suppose a set G of genes was sequenced in a collection P of patients, all of whom have the same disease.
Each sequenced gene5 g ∈ G partitions the set of patients into two subsets: the P(g), with patients with
a mutation in g, and the P¯(g), with patients with no mutation in g. The goal is to identify genes whose
mutational status is highly correlated with the survival time, in the sense that the survival distribution of
patients in P(g) is different from the survival distribution of patients in P¯(g). A key challenge in survival
analysis is dealing with censored patients whose exact survival time is unknown. Censoring occurs for a
variety of reasons, but the most common is that the study only lasts for a finite amount of time, and some
fraction of patients remain alive at the conclusion of the study. In addition, during the course of the study
patients may leave the study for a variety of reasons, that are unrelated to their treatment or disease state.
The censored survival time is the last time the patient was observed in the study, which is a lower bound for
the patient’s survival time6. Survival analysis assumes that censoring is non informative, i.e. the event that a
patient is censored is independent of the patient’s survival beyond the censoring time. The log-rank test [29]
(or family of tests) is the most commonly used non-parametric test for comparing the survival distribution
of two or more populations with data subject to censoring. The advantage of this test is that it includes
the censored data in its statistic, rather then removing it from the data. Since a large fraction of patients
may be censored (e.g., up to 94% in the data below), it is not desirable to remove this “missing data” from
consideration. In the section below, we describe two different versions of the log-rank test, the conditional
log-rank and the permutational log-rank test.
4This information was derived directly from the software manual and/or the publication cited in the manual.
5One may also consider mutations at different levels of resolution; e.g. partitioning patients according to mutations in individual
nucleotides or protein domains.
6In some references patients who survived the study are called right censored and patients who withdrew from the study are
called randomly censored.
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Basic survival analysis: the log-rank test
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Figure S4: (Top) The log-rank test
compares the Kaplan-Meier curves of
the two groups. (Middle) Survival
data is represented by sorting patients
by increasing survival. x represents
group labels for patients, and c repre-
sents censoring information (ci = 0
if event at time ti is censored, ci = 1
otherwise). (Bottom) The conditional
test is defined by a series of indepen-
dent contingency tables, conditioning
on the patients at risk at each non-
censored time. The permutational test
considers all
(
n
n1
)
possible locations
of the n1 patients with label 1 in the
vector x.
We focus on the two-samples log-rank test of comparing the survival
distribution of two groups, P0 and P1. Let t1 < t2 < · · · < tk be
the times of observed not censored events. Let Rj be the number of
patients at risk at time tj , i.e. the number of patients that survived (and
were not censored) up to this time, and let Rj,1 be the number of P1
patients at risk at that time. Let Oj be the number of observed, not
censored events in the interval [tj−1, tj ], and let Oj,1 be the number
of these events in group P1. If the survival distributions of P0 and
P1 are the same then in expectation E[Oj,1] = Oj
Rj,1
Rj
. The log-rank
statistic [29, 41] measures the sum of the deviations of Oj,1 from this
equal distribution7 expectation,
V =
k∑
j=1
(
Oj,1 −OjRj,1
Rj
)
. (2)
Since the log-rank statistic depends only on the order of the events
and not on their actual times, we can w.l.o.g. treat the survival data
(including censored times) as an ordered sequence of events, with no
two patients having identical survival times. Let ni = |Pi| be the num-
ber of patients in each set and let n = n0 + n1 be the total number of
patients. We represent the data with two binary vectors x ∈ {0, 1}n
and c ∈ {0, 1}n, where xi = 1 if the ith event was in P1 and xi = 0
otherwise; ci = 0 if the ith event was censored and ci = 1 otherwise.
Note that n1 =
∑n
i=1 xi. In this notation the log-rank statistic is
V = V (x, c) =
n∑
j=1
cj
(
xj − n1 −
∑j−1
i=0 xi
n− j + 1
)
. (3)
Clearly, the further V is from zero, the more likely it is the case that
the two survival distributions are different. To quantify this intuition,
we define the null hypothesis of no difference in the survival distribu-
tions of the two groups, and then compute the distribution of the test
statistic V under the null hypothesis. Two possible null distributions
are considered in the literature, defining two versions of the log-rank
test (see Figure S4).
Conditional log-rank test [31]. In this version, the null distribution
is defined by conditioning on Oj and Rj,1 for j = 1, . . . , k. If at time
tj there are a total of Rj patients at risk, including Rj,1 patients in P1,
then under the assumption of no difference in the distributions of P0
and P1, we expect the Oj events at that time to be split between P0
and P1 according to a hypergeometric distribution with parameters Rj ,
Rj,1, and Oj .
Under this null distribution the expectation of the log-rank statistic
7In some clinical applications one is more interested in either earlier or later events. In that case, the statistic is a weighted sum
of the deviations. Our results easily translate to the weighted version of the test.
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is 0, and its variance is σ2h =
∑k
j=1Oj
R1,j
Rj
(
1− R1,jRj
)
Rj−Oj
Rj−1 (Mantel-
Haenszel variance [31]. Note that this test does not assume equal dis-
tribution of censoring in the two groups. This property is important in clinical trials when patients in the two
groups are subject to different treatments that may affect their probability of leaving the trial. In the case
of cancer mutation data, under the null hypothesis it is unlikely that the presence of a mutation changes the
probability that a patient leaves the trial, and thus we do not face this difficulty. However, a major disadvan-
tage of this test is that the number of events in P1, generated by this distribution, is a random variable that is
equal to n1 only on average. In the case of an unbalanced population, where n1 is small, it can significantly
affect the computed p-value.
Permutational log-rank test [41]. In this version, we observe that under the null hypothesis the distribu-
tion of the group labels, xi’s, is independent of the survival information. Therefore, we consider the sample
space of all
(
n
n1
)
possible locations of the n1 patients of group P1 in the vector x, and each possibility is
assigned equal probability
(
n
n1
)−1. For this reason, the resulting distribution is usually called permutational
distribution of the log-rank statistic [41]. Under this null hypothesis the expectation of the log-rank statistic
is 0, and the variance [4] is σ2p =
n1n2
n(n−1)
(
k −∑ki=1 1Ri). Note that in this distribution the number of
patients in P1 is exactly n1. The validity of this log-rank test depends on the probability of censoring being
equal in the two groups. As discussed above this assumption holds in our application.
Estimating the p-value
Under both null distributions above, the expectation E[V ] = 0. Given an observed value v, its p-value is
Pr(|V | ≥ |v|). In the two null distributions the prefix sums of the log-rank statistic define a martingale,
and therefore, by the martingale central limit theorem [25], the normalized log-rank statistic V/σ, where σ
is either σh or σp, has an asymptotic N (0, 1) distribution, which gives an easy method for computing the
p-value. Furthermore, asymptotically the two variances σ2h and σ
2
p are the same [30], thus for large balanced
populations the two versions of the test give the same results. Therefore, the distinction between the two
versions of the test is mostly ignored in the literature, although there is some discussion of which variance
is the appropriate to use [4, 30].
The situation is drastically different in the setting of genome-wide cancer survival analysis. As was
reported in [28, 27] and we show in the next section, the Normal approximation gives a poor estimate for
the p-value in the range of population sizes inherent in the genome-wide association studies. Thus, we need
an efficient algorithm for computing a correct estimate of the p-values that does not depend on the Normal
approximation. Furthermore, we also report that in this range of parameters, the p-value of the log-rank
statistic is very sensitive to the choice of null distribution: since the conditional distribution matches the
problem parameters only in expectation, we prefer the permutational null distribution that matches exactly
the problem’s parameters.
Accuracy of Asymptotic Approximations
We applied the log-rank test based on asymptotic approximations to randomly generated survival and muta-
tion data. We focused on the case of unbalanced populations. We compared the p-values obtained from the
asymptotic approximations with the uniform distribution that is expected under the null hypothesis. We use
n to denote the total number of samples, and n1 the number of samples in the small population. Fig. S5a
shows that even when the number of patients in the small population is large (n1 = 100), when the im-
balance between populations increases, the accuracy of the asymptotic approximation decreases. Fig. S5b
shows that for a fixed ratio n1/n, the asymptotic approximation improves when the total populations size
increases. Fig. S5c shows that for a fixed n, the asymptotic approximation improves when the imbalance
decreases. In addition to the normal approximation, Fig. S5d includes the χ2 approximation, and shows
the results considering 105 data points with n = 500 total samples, n1 = 5%n samples with a mutation
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in the gene, and same survival distribution for all patients. In particular, the survival time comes from an
exponential distribution with the same expectation (equal to 30), and censoring variable from an exponential
distribution resulting in 30% of censoring. These results show that with n = 100, n1 must be > 20%n for
the asymptotic permutational approximation to be accurate, while with n = 500, n1 must be ≥ 5% for the
asymptotic permutational approximation to be accurate.
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Figure S5: Comparison of the p-values from asymptotic approximations and the uniform distribution. (a) Distribution
of p-values obtained using the conditional approximation, and distribution of p-values for the uniform distribution.
Generated considering 105 instances with n1 = 100 samples in the small population, different number n of samples in
total, and same survival distribution for all patients (≈ 40% censoring). (b) Distribution of p-values obtained using the
permutational approximation, and distribution of p-values for the uniform distribution. Generated considering 105 data
points with n1 = 5%n samples in the small population, n total samples, and no censoring. (c) Distribution of p-values
obtained using the permutational approximation, and distribution of p-values for the uniform distribution. Generated
considering 105 data points with n = 100 total samples, different values of n1, and no censoring. (d) Distribution of
p-values obtained using different approximations, and distribution of p-values for the uniform distribution. Generated
considering 105 instances with n = 500 total samples, n1 = 5%n samples with a mutations in the gene, and same
survival distribution for all patients (≈ 30% censoring).
21
Comparison of Exact Tests on Synthetic Data
Comparison of Exact Distributions
We find that the p-values from the permutational exact test are significantly closer (p < 10−3) to the empir-
ical p-values than the p-values obtained from the conditional exact test (Fig. S3).
We compared the accuracy of exact p-values for the permutational and conditional distributions in our
setting of unbalanced small populations using synthetic data. We generate synthetic data using two related
but different procedures. In the first procedure, we mutate a gene g in exactly a fraction f of all patients.
In the second procedure, we mutated a gene g in each patient independently with probability f . The sec-
ond procedure models the fact that mutations in a gene g are found in each patient independently with a
certain probability (that depends on the background mutation rate, the length of the gene, etc.). Thus, when
repeating a study on a cohort of patients of the same size only the expected number of patients in which g
is mutated is the same, and the observed number may vary. In both cases the survival information is gener-
ated from the same distribution for all patients. The survival time comes from the exponential distribution
with expectation equal to 30, and censoring variable from an exponential distribution resulting in 30% of
censoring. In Fig. S6a we compare the p-values computed from the exact permutational test and the exact
conditional test with the empirical p-values (obtained repeating the experiment 10000 times) for the first
distribution, while in Fig. S6b we compare the p-values computed from the exact permutational test and the
exact conditional test with the empirical p-values (obtained repeating the experiment 10000 times) for the
second distribution. In both cases the p-values (restricted to p-values ≤ 0.01) from the exact permutational
distribution have a significantly (p < 10−3) higher R coefficient than the p-values from the exact conditional
distribution when compared to the empirical p-values (considering the −log10 p-values in order to compute
the R coefficient). Therefore the p-values from the permutational exact test are significantly closer to the
empirical p-values than the p-values obtained from the conditional exact test.
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Figure S6: Comparison of the p-values from the exact tests and the empirical p-values for two different null distribu-
tions. The R coefficients comparing the −log10 exact p-values to the −log10 empirical p-values are the following: in
Fig. (a), permutational = 0.96, conditional = 0.88; in Fig (b), permutational = 0.72, conditional = 0.43. For both
distributions the difference between R coefficients is significant (p < 10−3). (a) Comparison of exact conditional p-
values, exact permutational p-values, and empirical p-values for n = 100, n1 = 5%n, and 30% censoring. Each point
represents an instance of survival data. (b) Comparison of exact conditional p-values, exact permutational p-values,
and empirical p-values for n = 100, expectation n1=5%n, and 30% censoring. Each point represents an instance of
survival data.
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Algorithms
As shown by the results in previous sections, to carry out an effective genome-wide survival analysis for
cancer somatic mutation we need an accurate estimate of the log-rank statistic p-values in the permutational
null distribution.
While the exact p-value in the conditional test can be computed in quadratic time [32, 20] no polyno-
mial time algorithm is known for the problem of computing the exact p-value for the permutational test.
Abd-Elfattah and Butler [1] use saddlepoint methods to determine the mid-p-values for the permutational
distribution. Heuristic methods may be derived from solutions to related problems. In particular the method
of Pagano and Tritchler [38], based on the Fast Fourier Transform (FFT), may be adapted to compute some
approximation of the exact p-value in polynomial time, but no guarantee on the accuracy of the approxi-
mation is provided by their method. Branch and bound methods (in the spirit of the method proposed by
Bejerano et al. [2]) may be used to compute the exact p-value, but may require exponential time in the worst
case. Note that since p-values can be really small, we do not want to use an MCMC approach, that requires
to sample a number of random permutations at least proportional to c−1 in order to obtain an estimate for a
p-value equal to c.
In the permutational distribution n and n1 are fixed, and thus computing the p-value is equivalent to
solving the following counting problem.
More Extreme Assignments Counting Problem: Given n, n1 ∈ N, with n1 ≤ n, v ∈ R and c ∈ {0, 1}n
determine the number of vectors x ∈ {0, 1}n that satisfy: ∑ni=1 xi = n1 and |V (x, c)| ≥ v.
Dividing the number of vectors x by
(
n
n1
)
, which defines the sample space size, gives the p-value of v.
Based on the similarity between this problem and Knapsack Counting Problem [13], we conjecture that the
problem may also be #P -complete.
FPTAS for the permutational distribution
We provide a Fully Polynomial Time Approximation Scheme (FPTAS) to estimate the p-value from the
permutational distribution, i.e. an algorithm that given n, n1, c, and v, for any ε > 0 computes an ε-
approximation of Pr(|V (x)| ≥ v) in time that is polynomial in n and ε−1. The FPTAS is derived from a
pair of recurrence relations that compute the exact probability, but may not terminate in polynomial time.
We then modify the process to obtain a fully polynomial time approximation scheme.
Exact computation. Let Vt(x) =
∑t
j=1 cj
(
xj − n1−
∑j−1
i=0 xi
n−j+1
)
be the test statistic V (x) at time t. Note
that since n, n1, and c are fixed, the statistic depends only on the values of x. Assume the observed log-rank
statistic has value v. The p-value of the observation v is the probability Pr(|V (x)| ≥ |v|) computed in
the probability space in which the n1 events of P1 are uniformly distributed among the n events. For any
0 ≤ t ≤ n and 0 ≤ r ≤ n1, let P (t, r, v) denote the joint probability Vt(x) ≤ v and exactly r events of P1
in the first t events,
P (t, r, v) = Pr
(
Vt(x) ≤ v AND
t∑
i=1
xi = r
)
.
Similarly, let Q(t, r, v) denote the joint probability of Vt(x) ≥ v and exactly r events of P1 in the first t
steps,
Q(t, r, v) = Pr
(
Vt(x) ≥ v AND
t∑
i=1
xi = r
)
.
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At time 0,
P (0, r, v) =
{
1 if r = 0 and v ≥ 0
0 otherwise,
and Q(0, r, v) =
{
1 if r = 0 and v ≤ 0
0 otherwise.
Given the values of P (t, r, v) and Q(t, r, v) for all v and r, we can compute the values of P (t+ 1, r, v)
and Q(t, r, v) using the following relations:
If ct+1 = 1 then
P (t+ 1, r, v) = (1− n1 − r
n− t )P (t, r, v+
n1 − r
n− t ) +
n1 − (r − 1)
n− t P (t, r− 1, v− (1−
n1 − (r − 1)
n− t )), and
Q(t+ 1, r, v) = (1− n1 − r
n− t )Q(t, r, v +
n1 − r
n− t ) +
n1 − (r − 1)
n− t Q(t, r − 1, v − (1−
n1 − (r − 1)
n− t )).
If ct+1 = 0 then
P (t+ 1, r, v) = (1− n1 − r
n− t )P (t, r, v) +
n1 − (r − 1)
n− t P (t, r − 1, v), and
Q(t+ 1, r, v) = (1− n1 − r
n− t )Q(t, r, v) +
n1 − (r − 1)
n− t Q(t, r − 1, v).
The process defined by these equation guarantees that the n events include n1 events of P1. Thus, for
r 6= n1, P (n, r, v) = 0 and Q(n, r, v) = 0, and the p-value is given by8
Pr(|V (x)| ≥ |v|) = P (n, n1,−|v|) +Q(n, n1, |v|).
The functions P (t + 1, r, v) and Q(t + 1, r, v) are step functions. To compute the function P (t + 1, r, v)
when ct+1 = 1, we note that as we vary v the value of P (t + 1, r, v) changes only at the points in which
P (t, r, v + n1−rn−t ) or P (t, r − 1, v − (1− n1−(rn−t )) change values. Thus, the function needs to be computed
only at these points.
At t = 0 the function P (0, r, v) assumes up to 2 values. If P (t, r, v) assumes m(t, r) values and
P (t, r − 1, v) assumes m(t, r − 1) values, then P (t+ 1, r, v) assumes up to m(t, r) +m(t, r − 1) values.
Similar relation hold for P (t+ 1, r, v) when ct+1 = 0, and for computing Q(t, r, v) in the two cases. Thus,
in n iterations the process computes the exact probabilities P (n, r, v) and Q(n, r, v), but it may have to
compute probabilities for an exponential number of different values of v in some iterations.
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Figure S7: Starting from the approximation P˜ (t, r, v) at time t that
uses ` values of v to approximate P (t, r, v), in the t + 1 iteration the
FPTAS computes an approximation Pˆ (t+1, r, v) for P (t+1, r, v) that
uses up to 2` values of v; then the approximation P˜ (t+ 1, r, v) is built
starting from Pˆ (t + 1, r, v) by appropriately reducing the number of
values of v considered, while maintaining guarantees on the approxi-
mation.
Approximation Algorithm. We first
note that since the probability space con-
sists of
(
n
n1
)
equal probability events,
all non-zero probabilities in our analy-
sis are ≥ n−n1 . For 0 < ε < 1,
fix ε1 such that (1 − ε1)−n = 1 +
ε. Note that 1 = O(/n). We dis-
cretize the interval of possible non-zero
probabilities [n−n1 , 1], using the val-
ues (1 − ε1)k, for k = 0, . . . , ` =
−n1 logn
log(1−ε1) = O(ε
−1nn1 log n). The
approximation algorithm computes esti-
8In the exact computation Q(n, n1, V ) = 1 − P (n, n1, V ), but in the approximate algorithm below we need to compute each
of the probability functions separately.
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mates for P (t, r, v) and Q(t, r, v) in two
separate processes.
Estimating P (t, r, v). Let P˜ (t, r, v) be a step function defined by a sequence of points vtk,r, k = 0, . . . , `.
The value of the function in the interval [vtk+1,r, v
t
k,r] is (1− ε1)k, and for v > vt0,r the value of the function
is 1. Consecutive points in the sequence may be the same (vtk+1,r = v
t
k,r), in that case the value of P˜ (t, r.v)
is (1 − ε1)kv , where kv = arg maxk[v ≤ vtk,r]. (Not that the sequence vtk,r, k = 0, . . . , ` is non-increasing
in k, since larger k corresponds to smaller probability.)
For t = 0, we define P˜ (0, r, v) by the set of points v0k,0 = 0 and v
0
k,r = ∞ for r > 0, k = 0, . . . , `.
These functions satisfy P˜ (0, r, v) = P (0, r, v) for all r and v.
Assume that iteration t+ 1 starts with a set of functions P˜ (t, r, v), for r = 0, . . . , n1 such that for all r
and v
(1− ε1)tP˜ (t, r, v) ≤ P (t, r, v) ≤ P˜ (t, r, v).
We show that iteration t + 1 computes functions P˜ (t + 1, r, v) with the same approximation properties.
(Figure S7 shows how the approximation at time t + 1 is computed from the approximation at time t.)
To compute an estimate for the functions P (t+ 1, r, v), r = 0, . . . , n1, we use the relations given in the
exact computation, estimating P (t, r, v) by P˜ (t, r, v). In the case ct+1 = 1 we use
Pˆ (t+ 1, r, v) = (1− n1 − r
n− t )P˜ (t, r, v +
n1 − r
n− t ) +
n1 − r
n− t P˜ (t, r − 1, v − (1−
n1 − r
n− t )),
and compute (for each r) the function at the 2` points corresponding to change in values in the functions
P˜ (t, r, v) and P˜ (t, r − 1, v):
vtk,r = v +
n1 − r
n− t and v
t
k,r−1 = v − (1−
n1 − r
n− t ), for k = 1, . . . , `.
In the case ct+1 = 0 we use
Pˆ (t+ 1, r, v) = (1− n1 − r
n− t )P˜ (t, r, v) +
n1 − r
n− t P˜ (t, r − 1, v),
and compute the function (for each r) in the 2` points vtk,r and v
t
k,r−1.
Let v1 ≤ v2 ≤ · · · ≤ v2` be the 2` points for which the value of Pˆ (t+1, r, v) was computed. We extend
the function Pˆ (t+ 1, r, v) to a step function over all values of v, such that Pˆ (t+ 1, r, v) = Pˆ (t+ 1, r, vj),
where j is the largest index such that v ≥ vj .
Since we computed the function Pˆ (t+ 1, r, v) in all points in which P˜ (t, r, v) and P˜ (t, r− 1, v) change
values, and by the assumptions on the values of P˜ (t, r, v), for all r and v we have
Pˆ (t+ 1, r, v)(1− ε1)t+1 ≤ P (t+ 1, r, v) ≤ Pˆ (t+ 1, r, v).
We now approximate the function Pˆ (t + 1, r, v) by a function P˜ (t + 1, r, v) that is defined by the
sequence of only ` values:
vjk,r = arg maxv
[P˜ (j, r, v) ≤ (1− ε1)k], k = 0, . . . , `.
Consider a value v such that vt+1k+1,r ≤ v < vt+1k,r . We have:
P (t+ 1, r, v) ≤ Pˆ (t+ 1, r, v) ≤ Pˆ (t+ 1, r, vt+1k,r ) ≤ P˜ (t+ 1, r, vt+1k,r ), (4)
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and
P (t+ 1, r, v) ≥ P (t+ 1, r, vt+1k+1,r) ≥ Pˆ (t+ 1, r, vt+1k,r )(1− ε1)t+1 ≥ P˜ (t+ 1, r, vt+1k,r )(1− ε1)t+1. (5)
Thus, our estimate P˜ (n, n1,−v) for P (V (x) ≤ −v) = P (n, n1,−v) satisfies
P (n, n1,−v) ≤ P˜ (n, n1,−v) ≤ P (n, n1,−v) 1
(1− ε1)t ≤ P (n, n1,−v)(1 + ε).
Estimating Q(t, r, v). Recall that Q(t, r, v) is the probability of exactly r events of P1 in the first t steps
and the statistic at time t is ≥ v,
Q(t, r, v) = Pr
 t∑
j=1
cj
(
xj − n1 −
∑j
i=1 xi
n− j
)
≥ v AND
t∑
i=1
xi = r
 .
Let Q˜(t, r, v) be a step function defined by a sequence of points vtk,r, k = 0, . . . , `. The value of the function
in the interval [vtk,r, v
t
k+1,r] is (1 − ε1)k and for v < vt0,r the value of the function is 1. Consecutive points
in the sequence may be the same (vtk+1,r = v
t
k,r), in that case the value of Q˜(t, r, v) is (1 − ε1)kv , where
kv = arg maxk[v ≥ vtk,r]. (Note that the sequence vtk,r, k = 0, . . . , ` is monotone non-decreasing in k,
since larger k corresponds to smaller probability.)
For t = 0, we define Q˜(0, r, v) by the set of points v0k,0 = 0 and v
0
k,r = ∞ for r > 0, k = 0, . . . , `.
These functions satisfy Q˜(0, r, v) = Q(0, r, v) for all r and v.
Assume that iteration t+ 1 starts with a set of functions Q˜(t, r, v), for r = 0, . . . , n1 such that for all r
and v
(1− ε1)tQ˜(t, r, v) ≤ Q(t, r, v) ≤ Q˜(t, r, v).
We show then iteration t+ 1 computes functions Q˜(t+ 1, r, v) with the same approximation properties.
To compute an estimates for the functions Q(t + 1, r, v), r = 0, . . . , n1, we use the relations given in
the exact computation, estimating Q(t, r, v) by Q˜(t, r, v). In the case ct+1 = 1 we use
Qˆ(t+ 1, r, v) = (1− n1 − r
n− t )Q˜(t, r, v +
n1 − r
n− t ) +
n1 − r
n− t Q˜(t, r − 1, v − (1−
n1 − r
n− t )),
and compute (for each r) the function at the 2` points corresponding to change in values in the functions
Q˜(t, r, v) and Q˜(t, r − 1, v):
vtk,r = v +
n1 − r
n− t and v
t
k,r−1 = v − (1−
n1 − r
n− t ), for k = 1, . . . , `.
In the case ct+1 = 0 we use
Qˆ(t+ 1, r, v) = (1− n1 − r
n− t )Q˜(t, r, v) +
n1 − r
n− t Q˜(t, r − 1, v),
and compute the function (for each r) in the 2` points vtk,r and v
t
k,r−1.
Let v1 ≤ v2 ≤ · · · ≤ v2` be the 2` points for which the value of Qˆ(t+1, r, v) was computed. We extend
the function Qˆ(t+ 1, r, v) to a step function over all values of v, such that Qˆ(t+ 1, r, v) = Qˆ(t+ 1, r, vj),
where j is the largest index such that v ≥ vj .
Since we computed the function Qˆ(t+ 1, r, v) in all points in which Q˜(t, r, v) and Q˜(t, r− 1, v) change
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values, and by the assumptions on the values of Q˜(t, r, v), for all r and v we have
Qˆ(t+ 1, r, v)(1− ε1)t+1 ≤ Q(t+ 1, r, v) ≤ Qˆ(t+ 1, r, v).
We now approximate the function Qˆ(t + 1, r, v) by a function Q˜(t + 1, r, v) that is defined by the
sequence of only ` values:
vjk,r = arg minv
[Q˜(j, r, v) ≤ (1− ε1)k], k = 0, . . . , `.
Consider a value v such that vt+1k,r ≤ v < vt+1k+1,r. We have:
Q(t+ 1, r, v) ≤ Qˆ(t+ 1, r, v) ≤ Qˆ(t+ 1, r, vt+1k,r ) ≤ Q˜(t+ 1, r, vt+1k,r ), (6)
and
Q(t+ 1, r, v) ≥ Q(t+ 1, r, vt+1k+1,r) ≥ Qˆ(t+ 1, r, vt+1k,r )(1− ε1)t+1 ≥ Q˜(t+ 1, r, vt+1k,r )(1− ε1)t+1. (7)
Thus, our estimate Q˜(n, n1, v) for Q(V (x) ≥ v) = Q(n, n1, v) satisfies
Q(n, n1, v) ≤ Q˜(n, n1, v) ≤ Q(n, n1, v) 1
(1− ε1)t ≤ Q(n, n1, v)(1 + ε).
From the discussion above the following theorem is readily derived.
Theorem 1. The algorithm above is a FPTAS for computing Pr(|V (x)| ≥ |v|).
Proof. We first consider the approximation ratio. Note that Pr(|V (x)| ≥ |v|) = Pr(V (x) ≥ |v|) +
Pr(V (x) ≤ −|v|); from the discussion above we have that Pr(V (x) ≤ P (n, n1,−|v|) ≤ Pr(V (x)(1 + ε)
and Pr(V (x) ≥ |v|) ≤ Q(n, n1, |v|) ≤ Pr(V (x)(1 + ε), therefore if we define p˜ = P (n, n1,−|v|) +
Q(n, n1, |v|) we have that Pr(|V (x)| ≥ |v|) ≤ p˜ ≤ (1 + ε) Pr(|V (x)| ≥ |v|).
The run-time of each iteration is O(`n1) = O(ε−1nn21 log n) and there are n iterations, thus for any
ε > 0 the algorithm computes an ε-approximation in O(ε−1n2n21 log n) time.
FPTAS running time
We ran experiments to study how the running time of the FTPAS varies for different values of n, n1, and
ε. We also compared the running time of the FPTAS with the running time of the exhaustive algorithm for
permutational distribution. For simplicity, in our tests we assumed no censoring (i.e., c = 1n). Results
are shown in Figure S8. Figure S8a shows the average runtime of the FPTAS with n1 = 10, ε = 5,
for different values of n. (Standard deviations are not shown since they are very small compared to the
runtime.) For the same instances we also ran the exhaustive algorithm 10 times, stopping it after 5 hours
(i.e., 18000 seconds) if it did not terminate. Results for the exhaustive algorithm are shown in Figure S8a
as well. The starred (∗) values of n are values for which the exhaustive algorithm was stopped after 5 hours
in each of the 10 runs. The exhaustive algorithm is practical only for very small values of n, while the
FPTAS can be used for much larger values of n. Figure S8b shows how the runtime of the FPTAS varies
for different values of n1, with n = 100, ε = 5. As expected the runtime increases with n1, but it is still
practical for values of n1 up to 0.2n. We report the runtime of the exhaustive algorithm for comparison.
Note that for n = 100, n1 = 20 the exhaustive algorithm would take more than 160 years even running
on a 100 Ghz machine under the unrealistic assumption that it could compute the log-rank statistic of a
vector x every clock cycle. Figure S8c shows how the runtime of the FPTAS varies for different values of
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Figure S8: Running time of the FPTAS, and its comparison with the running time of the exhaustive enumeration
algorithm, for different values of the parameters. (a) Runtime of FPTAS and of the exhaustive enumeration for different
values of n, and for n1 = 10, ε = 5, no censoring. (b) Runtime of FPTAS and of the exhaustive enumeration for
n = 10, ε = 5, no censoring, and different values of n1. (c) Runtime of the FPTAS for different values of ε, and for
n = 100, n1 = 10, no censoring.
the approximation parameter ε. We measured the runtime over 10 runs with n = 100, n1 = 10, and no
censoring. As expected, the runtime decreases by increasing ε.
Cancer data
TCGA data
We analyzed somatic mutation and clinical data, including survival information, from the TCGA data portal
(https://tcga-data.nci.nih.gov/tcga/). In particular we considered single nucleotide vari-
ants (SNPs) and small indels for colorectal carcinoma (COADREAD), glioblastoma multiforme (GBM),
kidney renal clear cell carcinoma (KIRC), lung squamous cell carcinoma (LUSC), ovarian serous adenocar-
cinoma (OV), and uterine corpus endometrial carcinoma (UCEC). We restricted our analysis to patients for
which somatic mutation and survival data were both available. We only considered genes mutated in > 1%
of patients. Since genes mutated in the same patients have the same association to survival, we collapsed
them into metagenes, recording the genes that appear in a metagene. Table S2 shows a number of statistics
for each dataset. Fig. S9 shows the comparison between the exact permutational p-value, computed using
the FPTAS when the gene was mutated in < 10% of the samples and the R survdiff p-value or the exact
conditional p-value for each considered gene.
We compared the genes reported in the top positions by the different tests. The number of genes shared
in the top positions of the lists obtained by the exact permutational test and the exact conditional test, and
by the exact permutational test and R survdiff for the different cancer types are: in COADREAD, 6
genes are in the top 10 positions by the exact permutational test and by R survdiff, and 7 in the top 10
positions by the exact permutational test and by the exact conditional test, while 17 genes are in the top 25
positions by the exact permutational test and by R survdiff, and 21 in the top 25 positions by the exact
permutational test and by the exact conditional test; in GBM, no gene is in the top 10 positions by the exact
permutational test and by R survdiff, and 2 in the top 10 positions by the exact permutational test and
by the exact conditional test, while no gene is in the top 25 positions by the exact permutational test and by
R textttsurvdiff, and 2 in the top 25 positions by the exact permutational test and by the exact conditional
test; in KIRC, 2 genes are in the top 10 positions by the exact permutational test and by R survdiff,
and 4 in the top 10 positions by the exact permutational test and by the exact conditional test, while 9 genes
are in the top 25 positions by the exact permutational test and by R survdiff, and 15 in the top 25
positions by the exact permutational test and by the exact conditional test; in LUSC, no gene is in the top
10 positions by the exact permutational test and by R survdiff, and no gene is in the top 10 positions
by the exact permutational test and by the exact conditional test, while 1 gene is in the top 25 positions by
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the exact permutational test and by R survdiff, and 4 in the top 25 positions by the exact permutational
test and by the exact conditional test; in OV, no gene is in the top 10 positions by the exact permutational
test and by R survdiff, and 1 gene is in the top 10 positions by the exact permutational test and by
the exact conditional test, while 3 genes are in the top 25 positions by the exact permutational test and by
R survdiff, and 7 in the top 25 positions by the exact permutational test and by the exact conditional
test; in UCEC, 5 genes are in the top 10 positions by the exact permutational test and by R survdiff, and
7 in the top 10 positions by the exact permutational test and by the exact conditional test, while 15 genes are
in the top 25 positions by the exact permutational test and by R survdiff, and 21 in the top 25 positions
by the exact permutational test and by the exact conditional test.
Table S3, Table S4, and Table S5 report the 10 genes with smallest p-values identified using the exact
permutational test, the exact conditional test, or R survdiff for the six cancer datasets. For each cancer
type, the top 10 genes, their rank, and p-value using the exact permutational test, the exact conditional
test, and R survdiff are reported. The number of samples with a mutation in the gene and refences
supporting the association of mutations in the gene with survival are also reported.
Table S2: Parameters of the cancer datasets analyzed.
dataset num. patients % censoring num. mutated genes num. genes mutated > 1%.
COADREAD 188 92% 2716 1099
GBM 268 30% 3702 1689
KIRC 292 74% 4448 1879
LUSC 175 60% 8465 5776
OV 315 43% 3740 665
UCEC 235 93% 8304 5792
For each dataset we show: the number of patients with both mutation and survival data; the percentage of patients with censored
survival data; the number of (meta)genes mutated in at least one sample; the number of (meta)genes mutated in more than 1% of
all samples.
Published Cancer Studies
We analyzed differences between survival distributions reported in two published genomic studies [22, 47].
We considered only cases where the smallest population included at most 30% of all samples. We compared
the exact permutational p-value with the p-value reported in the publications obtained using asymptotic
approximations. Since the data for these studies is not publicly available, we inferred the data necessary
to perform the log-rank test using the figures in the publications. In particular, since the exact time of
events (censored or not) is not used by the log-rank test, we only inferred the order of events into the
two populations and the censoring information. We then used R survdiff to obtain the p-value from the
asymptotic approximation, and compared it with the p-value reported in the paper to validate the information
we inferred from the figures.
In particular, for [22] we considered:
• Figure 2L: population sizes: 2 and 14. Reported p = 0.012; R survdiff p = 0.012; exact
permutational p = 0.017;
• Figure 2I: population sizes: 8 and 48. Reported p < 10−4; R survdiff p = 6 × 10−6; exact
permutational p = 2× 10−3;
• Figure 2H: population sizes: 9 and 21. Reported p = 3.2 × 10−3; R survdiff p = 3.2 × 10−3;
exact permutational p = 1.1× 10−2.
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Table S3: The 10 genes with smallest p-values identified using the exact permutational test in cancer data. For each
cancer type, we show the top 10 genes, their rank, and p-value using the exact permutational test, the exact conditional
test, and R survdiff. The number of samples with a mutation in the gene and references supporting the association
of mutations in the gene with survival are also reported.
exact permutational exact conditional R survdiff
cancer type gene rank p rank p rank p num. mut. refs
COADREAD PTPRM 1 5.20e-03 4 2.30e-03 10 1.74e-05 8
DOCK9 2 9.18e-03 3 1.72e-03 5 4.25e-08 6
VPS13B 3 1.22e-02 1 3.57e-04 1 6.21e-12 8
KRAS 4 1.29e-02 14 1.75e-02 82 1.40e-02 85 [19]
ERBB4 5 1.33e-02 2 5.89e-04 3 2.16e-10 8
CACNA1E 6 2.82e-02 7 8.68e-03 21 1.38e-04 7
PCDH11X 7 3.90e-02 12 1.49e-02 37 7.42e-04 7
ZNF804B 8 3.97e-02 5 2.92e-03 2 1.07e-10 5
AQPEP 9 4.86e-02 6 5.38e-03 4 2.55e-08 5
FBXW7 10 5.58e-02 64 7.95e-02 142 5.75e-02 21 [23, 7]
GBM IDH1 1 6.73e-05 2 4.79e-03 27 3.76e-03 15 [37, 35]
MED12L 2 1.19e-03 8 1.11e-02 62 1.31e-02 3
EMILIN1 3 2.77e-03 45 3.18e-02 100 3.17e-02 4
ATP6V0A4 4 3.11e-03 77 4.72e-02 101 3.29e-02 4
VARS2 5 7.67e-03 64 4.11e-02 111 3.80e-02 3 [11]
GALR1 6 8.67e-03 119 6.97e-02 156 6.61e-02 3
KCNH4 7 1.13e-02 108 6.16e-02 125 4.57e-02 3
CXorf22 8 1.29e-02 47 3.26e-02 102 3.32e-02 8
ITGAM 9 1.54e-02 57 3.65e-02 109 3.73e-02 6
PLXNB3 10 1.62e-02 99 5.63e-02 141 5.67e-02 6
KIRC CDCA2 1 8.54e-04 1 1.75e-04 7 6.15e-10 6
ATP10D 2 1.91e-03 3 6.15e-04 5 3.55e-12 3
TDRD7 3 3.66e-03 5 1.50e-03 10 5.00e-09 3
KIF27 4 4.48e-03 13 6.23e-03 27 1.19e-04 4
RELN 5 5.99e-03 23 1.08e-02 44 6.37e-04 4
TOPORS 6 6.50e-03 8 3.42e-03 14 8.83e-07 3
TCF20 7 6.89e-03 17 8.40e-03 46 7.18e-04 6
CHD7 8 8.41e-03 11 4.60e-03 30 1.51e-04 7
BAP1 9 9.72e-03 37 1.62e-02 98 1.23e-02 27 [17]
BCL9 10 1.10e-02 16 7.57e-03 19 3.67e-05 3
LUSC ATXN10 1 3.87e-05 121 3.18e-02 229 2.41e-02 3
ZNF304 2 4.00e-05 38 9.10e-03 166 1.14e-02 5
LINGO1 3 7.61e-05 83 2.15e-02 210 1.87e-02 4
C10orf79 4 8.80e-05 16 4.80e-03 116 4.91e-03 9
SPANXN1 5 1.14e-04 62 1.66e-02 190 1.57e-02 5
OR5AS1 6 1.43e-04 31 8.24e-03 146 8.59e-03 7
SLC7A13 7 1.89e-04 56 1.55e-02 203 1.80e-02 5
CCDC85A 8 3.12e-04 25 7.01e-03 142 7.95e-03 9
CIT 9 4.43e-04 132 3.49e-02 271 3.00e-02 4
DUSP27 10 4.53e-04 14 3.85e-03 117 4.93e-03 11
OV DFNB31 1 5.61e-04 5 1.65e-02 18 1.23e-02 4
ERN2 2 9.16e-04 13 2.60e-02 24 2.25e-02 5
NCOA3 3 1.37e-03 11 2.45e-02 21 1.75e-02 4
CIC 4 3.72e-03 18 3.12e-02 26 2.47e-02 4
PKP4 5 5.40e-03 20 3.45e-02 31 3.33e-02 5
BRCA2 6 6.20e-03 22 3.58e-02 32 3.45e-02 9 [3, 9]
MYST4 7 1.76e-02 74 9.86e-02 71 8.00e-02 5
OVGP1 8 1.77e-02 38 6.05e-02 36 4.50e-02 4
ADAR 9 1.77e-02 68 9.55e-02 64 7.08e-02 4
PCDH9 10 1.77e-02 73 9.81e-02 66 7.36e-02 4
UCEC CTGF 1 6.87e-04 1 5.23e-04 6 3.68e-12 3
KRT6C 2 4.41e-03 2 9.98e-04 2 0.00e+00 3
FAT3 3 5.88e-03 36 1.91e-02 166 5.70e-03 23
LSS 4 6.96e-03 3 1.82e-03 3 7.61e-14 3
ARID1A 5 9.74e-03 29 1.81e-02 219 1.21e-02 73 [42]
EIF2C4 6 1.13e-02 5 4.02e-03 8 9.56e-10 3
DMD 7 1.18e-02 33 1.90e-02 167 5.77e-03 28
CPNE8 8 1.24e-02 6 4.81e-03 13 5.98e-09 3
TLR2 9 1.35e-02 4 2.96e-03 7 3.68e-11 5
CFP 10 1.70e-02 7 5.42e-03 14 2.78e-08 5
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Table S4: The 10 genes with smallest p-values identified using the exact conditional test in cancer data. For each
cancer type, we show the top 10 genes, their rank, and p-value using the exact permutational test, the exact conditional
test, and R survdiff. The number of samples with a mutation in the gene and references supporting the association
of mutations in the gene with survival are also reported.
exact permutational exact conditional R survdiff
cancer type gene rank p rank p rank p num. mut. refs
COADREAD VPS13B 3 1.22e-02 1 3.57e-04 1 6.21e-12 8
ERBB4 5 1.33e-02 2 5.89e-04 3 2.16e-10 8
DOCK9 2 9.18e-03 3 1.72e-03 5 4.25e-08 6
PTPRM 1 5.20e-03 4 2.30e-03 10 1.74e-05 8
ZNF804B 8 3.97e-02 5 2.92e-03 2 1.07e-10 5
AQPEP 9 4.86e-02 6 5.38e-03 4 2.55e-08 5
CACNA1E 6 2.82e-02 7 8.68e-03 21 1.38e-04 7
DOCK3 11 6.21e-02 8 1.11e-02 6 3.92e-06 3
IGF1R 14 6.61e-02 9 1.26e-02 7 8.95e-06 3
ZNF568 16 7.26e-02 10 1.48e-02 11 2.50e-05 3
GBM TBC1D2 33 5.51e-02 1 3.69e-03 4 7.96e-05 5
IDH1 1 6.73e-05 2 4.79e-03 27 3.76e-03 15 [37, 35]
HDAC9 52 8.72e-02 3 5.12e-03 1 6.13e-06 3
ATP13A2 53 8.77e-02 4 6.36e-03 8 3.71e-04 6
CASKIN2 46 7.92e-02 5 6.88e-03 5 1.59e-04 4
GRM7 61 9.95e-02 6 8.68e-03 2 7.33e-05 3
MYST3 62 1.00e-01 7 8.88e-03 3 7.86e-05 3
MED12L 2 1.19e-03 8 1.11e-02 62 1.31e-02 3
BID 54 8.96e-02 9 1.14e-02 12 7.07e-04 4
NFYC 68 1.06e-01 10 1.16e-02 6 1.96e-04 3
KIRC CDCA2 1 8.54e-04 1 1.75e-04 7 6.15e-10 6
FBXO43 26 2.19e-02 2 2.46e-04 4 4.44e-16 5
ATP10D 2 1.91e-03 3 6.15e-04 5 3.55e-12 3
EZH2 42 2.89e-02 4 8.07e-04 2 0.00e+00 3
TDRD7 3 3.66e-03 5 1.50e-03 10 5.00e-09 3
PKD1L3 40 2.79e-02 6 3.17e-03 13 6.48e-07 5
RASEF 46 3.21e-02 7 3.19e-03 6 5.48e-11 3
TOPORS 6 6.50e-03 8 3.42e-03 14 8.83e-07 3
PCDH11X 47 3.26e-02 9 4.16e-03 8 1.05e-09 3
ZFAT 48 3.43e-02 10 4.57e-03 9 2.65e-09 3
LUSC ZNF527 13 5.00e-04 1 2.08e-04 12 6.00e-07 9
ZNF557 75 7.07e-03 2 4.09e-04 3 1.96e-13 3
CHTF18 1014 2.13e-01 3 5.24e-04 1 0.00e+00 4
CNGA4 42 3.44e-03 4 1.19e-03 14 2.27e-06 5
BCL11A 362 6.00e-02 5 1.28e-03 11 5.80e-07 7
SIN3B 111 1.23e-02 6 1.55e-03 6 1.00e-08 3
ANKRD11 487 8.70e-02 7 1.70e-03 7 2.41e-08 5
RLTPR 656 1.21e-01 8 1.94e-03 2 7.70e-14 3
NARG2 120 1.35e-02 9 2.15e-03 8 8.62e-08 3
ATP2B2 176 2.34e-02 10 2.42e-03 23 2.32e-05 7
OV PABPC3 39 4.42e-02 1 5.95e-03 2 1.04e-04 4
KIAA0913 82 1.21e-01 2 8.65e-03 1 6.22e-05 4
NIPBL 110 1.85e-01 3 1.23e-02 3 2.56e-04 5
PCDHA9 46 5.67e-02 4 1.23e-02 4 8.84e-04 4
DFNB31 1 5.61e-04 5 1.65e-02 18 1.23e-02 4
RBM44 91 1.49e-01 6 1.85e-02 5 9.99e-04 4
TNRC18B 55 7.05e-02 7 1.95e-02 7 2.96e-03 4
PTCH1 65 8.80e-02 8 2.05e-02 10 5.46e-03 6
EFCAB6 124 2.07e-01 9 2.07e-02 6 1.56e-03 5
PCDH15 50 6.10e-02 10 2.24e-02 12 6.58e-03 5
UCEC CTGF 1 6.87e-04 1 5.23e-04 6 3.68e-12 3
KRT6C 2 4.41e-03 2 9.98e-04 2 0.00e+00 3
LSS 4 6.96e-03 3 1.82e-03 3 7.61e-14 3
TLR2 9 1.35e-02 4 2.96e-03 7 3.68e-11 5
EIF2C4 6 1.13e-02 5 4.02e-03 8 9.56e-10 3
CPNE8 8 1.24e-02 6 4.81e-03 13 5.98e-09 3
CFP 10 1.70e-02 7 5.42e-03 14 2.78e-08 5
TUT1 11 1.75e-02 8 5.65e-03 15 4.09e-08 5
SH3TC2 15 1.87e-02 9 7.39e-03 18 2.31e-07 4
USP20 14 1.86e-02 10 7.68e-03 19 3.61e-07 3
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Table S5: The 10 genes with smallest p-value identified using R survdiff in cancer data. For each cancer type,
we show the top 10 genes, their rank, and p-value using the exact permutational test, the exact conditional test, and
R survdiff. The number of samples with a mutation in the gene and references supporting the association of
mutations in the gene with survival are also reported.
exact permutational exact conditional R survdiff
cancer type gene rank p rank p rank p num. mut. refs
COADREAD VPS13B 3 1.22e-02 1 3.57e-04 1 6.21e-12 8
ZNF804B 8 3.97e-02 5 2.92e-03 2 1.07e-10 5
ERBB4 5 1.33e-02 2 5.89e-04 3 2.16e-10 8
AQPEP 9 4.86e-02 6 5.38e-03 4 2.55e-08 5
DOCK9 2 9.18e-03 3 1.72e-03 5 4.25e-08 6
DOCK3 11 6.21e-02 8 1.11e-02 6 3.92e-06 3
IGF1R 14 6.61e-02 9 1.26e-02 7 8.95e-06 3
ARAP1 50 1.75e-01 35 4.74e-02 8 1.03e-05 3
PRKCB 51 1.75e-01 36 4.74e-02 9 1.03e-05 3
PTPRM 1 5.20e-03 4 2.30e-03 10 1.74e-05 8
GBM HDAC9 52 8.72e-02 3 5.12e-03 1 6.13e-06 3
GRM7 61 9.95e-02 6 8.68e-03 2 7.33e-05 3
MYST3 62 1.00e-01 7 8.88e-03 3 7.86e-05 3
TBC1D2 33 5.51e-02 1 3.69e-03 4 7.96e-05 5
CASKIN2 46 7.92e-02 5 6.88e-03 5 1.59e-04 4
NFYC 68 1.06e-01 10 1.16e-02 6 1.96e-04 3
ZNF618 70 1.07e-01 11 1.20e-02 7 2.26e-04 3
ATP13A2 53 8.77e-02 4 6.36e-03 8 3.71e-04 6
LIMCH1 73 1.10e-01 13 1.36e-02 9 3.76e-04 3
LMX1B 79 1.15e-01 14 1.53e-02 10 5.16e-04 3
KIRC ARHGAP28 495 3.76e-01 15 7.25e-03 1 0.00e+00 3
EZH2 42 2.89e-02 4 8.07e-04 2 0.00e+00 3
PRKG2 508 3.91e-01 34 1.45e-02 3 3.33e-16 3
FBXO43 26 2.19e-02 2 2.46e-04 4 4.44e-16 5
ATP10D 2 1.91e-03 3 6.15e-04 5 3.55e-12 3
RASEF 46 3.21e-02 7 3.19e-03 6 5.48e-11 3
CDCA2 1 8.54e-04 1 1.75e-04 7 6.15e-10 6
PCDH11X 47 3.26e-02 9 4.16e-03 8 1.05e-09 3
ZFAT 48 3.43e-02 10 4.57e-03 9 2.65e-09 3
TDRD7 3 3.66e-03 5 1.50e-03 10 5.00e-09 3
LUSC CHTF18 1014 2.13e-01 3 5.24e-04 1 0.00e+00 4
RLTPR 656 1.21e-01 8 1.94e-03 2 7.70e-14 3
ZNF557 75 7.07e-03 2 4.09e-04 3 1.96e-13 3
CD33 681 1.27e-01 13 3.71e-03 4 3.90e-10 3
SPATA22 703 1.34e-01 20 5.15e-03 5 9.90e-09 3
SIN3B 111 1.23e-02 6 1.55e-03 6 1.00e-08 3
ANKRD11 487 8.70e-02 7 1.70e-03 7 2.41e-08 5
NARG2 120 1.35e-02 9 2.15e-03 8 8.62e-08 3
ZC3H12C 1088 2.27e-01 28 7.46e-03 9 2.85e-07 4
VN1R4 712 1.36e-01 29 7.78e-03 10 3.83e-07 3
OV KIAA0913 82 1.21e-01 2 8.65e-03 1 6.22e-05 4
PABPC3 39 4.42e-02 1 5.95e-03 2 1.04e-04 4
NIPBL 110 1.85e-01 3 1.23e-02 3 2.56e-04 5
PCDHA9 46 5.67e-02 4 1.23e-02 4 8.84e-04 4
RBM44 91 1.49e-01 6 1.85e-02 5 9.99e-04 4
EFCAB6 124 2.07e-01 9 2.07e-02 6 1.56e-03 5
TNRC18B 55 7.05e-02 7 1.95e-02 7 2.96e-03 4
FARSA 103 1.70e-01 15 2.89e-02 8 3.84e-03 4
PLEKHG1 104 1.70e-01 16 2.94e-02 9 4.02e-03 4
PTCH1 65 8.80e-02 8 2.05e-02 10 5.46e-03 6
UCEC KLHL29 51 4.08e-02 24 1.39e-02 1 0.00e+00 3
KRT6C 2 4.41e-03 2 9.98e-04 2 0.00e+00 3
LSS 4 6.96e-03 3 1.82e-03 3 7.61e-14 3
MYC 86 7.56e-02 31 1.87e-02 4 6.05e-13 4
SH3GL1 53 4.86e-02 32 1.87e-02 5 6.05e-13 3
CTGF 1 6.87e-04 1 5.23e-04 6 3.68e-12 3
TLR2 9 1.35e-02 4 2.96e-03 7 3.68e-11 5
EIF2C4 6 1.13e-02 5 4.02e-03 8 9.56e-10 3
LOC342346 59 5.83e-02 47 2.79e-02 9 5.35e-09 3
RAB40AL 60 5.83e-02 48 2.79e-02 10 5.35e-09 3
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Figure S9: Comparison of the p-values from the exact permutational test, the exact conditional test, and the asymp-
totic approximation (as implemented in the survdiff package in R ) for cancer datasets COADREAD, GBM, KIRC,
LUSC, OV, UCEC. (a,b,c,d): Each data point represents a gene, and the p-values computed using the exact permuta-
tional test and the p-values from R survdiff for the gene are shown. (e,f,g,h): Each data point represents a gene,
and the p-values computed using the exact permutational test and the exact condtional test for the gene are shown.
For [47] we considered:
• Figure 3A: population sizes: 14 and 115. Reported p = 2 × 10−3; R survdiff p = 2.3 × 10−3;
exact permutational p = 4.8× 10−4;
• Figure 3B: population sizes: 14 and 38. Reported p < 10−3; R survdiff p = 6 × 10−6; exact
permutational p = 5× 10−4.
Comparison of Exact Permutational Test and Cox Proportional-Hazard Model on Synthetic
Data
Three asymptotically equivalent statistical tests are commonly used to assess significance using the Cox
Proportional-Hazard model: the score test, the Wald test, and the likelihood ratio test. All the three tests are
based on an asymptotic approximation for the distribution of the test statistic.
We applied the three tests (score test, Wald test, and likelihood ratio test) to assess statistical signifi-
cance under the Cox Proportional-Hazard Model, on randomly generated survival and mutation data, where
no mutation is associated with survival. The three tests are based on asymptotic approximations for the dis-
tribution of the test statistic. We focused on the case of unbalanced populations. In particular, we considered
n = 100 total patients, and n1 = 5 patients in the small population. We used the R coxph package to com-
pute the p-values. Fig. S10a shows that for the score test and the Wald test the asymptotic approximation is
inaccurate, while the asymptotic approximation is pretty accurate for the likelihood ratio test.
We then compared the accuracy of the p-values obtained with the exact permutational test and the p-
values from the Cox likelihood ratio test. In particular, we use synthetic data, generated using the same
distribution for the survival time and for the censoring time for all patients, and using different procedures to
generate the mutation data. More specifically, we compared the empirical p-value (obtained by generating
the data a number of times using the same parameters for the distribution) with the p-values from the exact
permutational test and the p-values from the Cox likelihood ratio test using synthetic data. We generate the
mutation data using two related but different procedures. In the first procedure, we mutate a gene g in exactly
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a fraction f of all patients. In the second procedure, we mutated a gene g in each patient independently with
probability f . The second procedure models the fact that mutations in a gene g are found in each patient
independently with a certain probability (that depends on the background mutation rate, the length of the
gene, etc.). Thus, when repeating a study on a cohort of patients of the same size, only the expected number
of patients in which g is mutated is the same, and the observed number may vary. In both cases, the survival
information is generated from the same distribution for all patients. In particular, the survival time comes
from the exponential distribution with expectation equal to 30, and censoring variable from an exponential
distribution resulting in 30% of censoring. In Fig. S10b we compare the p-values computed from the exact
permutational test and the Cox likelihood ratio test with the empirical p-values (obtained repeating the
experiment 10000 times) for the first distribution, while in Fig. S10c we compare the p-values computed
from the exact permutational test and the Cox likelihood ratio test with the empirical p-values (obtained
repeating the experiment 10000 times) for the second distribution. In both cases, the p-values (restricted to
p-values≤ 0.01) from the exact permutational distribution have higher R coefficients than the p-values from
the Cox likelihood ratio test when compared to the empirical p-values (considering the −log10 p-values in
order to compute the R coefficient).
The Cox proportional-hazards model is often used to correct for other variables that may be correlated
to survival, like age, gender, or tumor stage. While the multivariate case is not the focus of this work, in this
scenario a common rule of thumb [12, 39, 40] states that Cox models should be used with a minimum of 10
outcome events per predictor variable to obtain reliable results. This limits its applicability to moderately
frequent events even in large genomic studies. For example, if we include three predictor variables in the
model in addition to the mutation status of a gene, then only two of our seven cancer datasets (LUSC
and UCEC) have more than 3 genes (7 and 8, respectively) that have the minimum recommended number
of mutations. Extensions of the exact test presented here might prove useful in such settings of a small
number of events per predictor variable. In particular, a stratified log-rank test using an exact distribution is
a promising alternative.
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Figure S10: Comparison of the p-values from asymptotic approximations for the Cox Proportional-Hazard model
and the uniform distribution, and comparison of the p-values from exact permutational tests and the Cox likelihood
ratio test with the empirical p-values for two different null distributions. (a) Distribution of p-values obtained using
the asymptotic approximation for the Cox Proportional-Hazard model and the distribution of p-values for the uniform
distribution. Generated considering 9 × 105 instances with n = 100 total samples, n1 = 5 samples in the small
population and same survival distribution for all patients (no censoring). (b) Comparison of Cox likelihood ratio p-
values, exact permutational p-values, and empirical p-values for n = 100, n1 = 5%n, and 30% censoring. Each point
represents an instance of survival data. (c) Comparison of Cox likelihood ratio p-values, exact permutational p-values,
and empirical p-values for n = 100, expectation(n1)=5%n, and 30% censoring. Each point represents an instance of
mutations and survival data. The R coefficients comparing the−log10 exact p-values to the−log10 empirical p-values
are the following: in Fig. (b), permutational = 0.96, Cox likelihood ratio = 0.70; in Fig (c), permutational = 0.72,
Cox likelihood ratio = 0.46. For both distributions the difference between R coefficients is significant (p < 10−3).
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